Early treated HIV-1 positive individuals demonstrate similar restriction factor expression profile as long-term non-progressors

EBioMedicine. 2019 Mar:41:443-454. doi: 10.1016/j.ebiom.2019.02.006. Epub 2019 Feb 12.

Abstract

Background: A wide range of host restriction factors (RF) become upregulated upon HIV-1 infection to suppress viral infectivity and may aid viremic control in vivo. This cross-sectional study evaluated HIV-1 RFs and dependency factors in HIV infected individuals with progressive or non-progressive infection, as well as in early and late treated cohorts that exhibit different viro-immunological profiles due to differences in timing of treatment-initiation.

Methods: The expression profile of IFIT1, MX1, APOBEC3G, SAMHD1, BST2 (encoding TETHERIN), TRIM5, MX2, SLFN11, PAF1, PSIP1 (encoding LEDGF/p75), and NLRX1 was measured by qPCR in 104 HIV-1 positive individuals: seroconverters (SRCV; n = 19), long term non-progressors (LTNP; n = 17), viremic progressors (VP; n = 12), patients treated during seroconversion (Early treated; n = 24) or chronic infection (Late treated; n = 32), and non-infected controls.

Findings: Expression levels of early treated HIV-1 positive individuals were significantly upregulated in comparison to late treated patients (IFIT1: p = 0·0003; MX1: p = 0·008; APOBEC3G: p = 0·002; SAMHD1: p = 0·0008; SLFN11: p < 0·0001; BST2: p < 0·0001). Similarly, SLFN11, BST2, and SAMHD1 were highly expressed in LTNPs at comparable levels as in early treated HIV-1 positive individuals. Furthermore, SLFN11 and SAMHD1 expression negatively correlated with total and integrated HIV-1 DNA levels.

Interpretation: Early treatment initiation maintains initial RF elevation even after a decade of ART. Elevated expression of SLFN11, BST2, and SAMHD1 in LTNP and early treated subjects implies that these RFs may be associated with spontaneous virological control.

Keywords: Cohorts; Early treatment; HIV-1 infection; LTNP; Restriction factors.

MeSH terms

  • Adult
  • Antiretroviral Therapy, Highly Active
  • Biomarkers
  • CD4 Lymphocyte Count
  • Disease Progression
  • Female
  • Gene Expression Profiling
  • Gene Expression Regulation*
  • HIV Infections / drug therapy
  • HIV Infections / genetics*
  • HIV Infections / immunology
  • HIV Infections / virology*
  • HIV Seropositivity
  • HIV-1*
  • Host-Pathogen Interactions / genetics*
  • Humans
  • Male
  • Middle Aged
  • Phenotype
  • Time-to-Treatment
  • Viral Load
  • Virus Replication

Substances

  • Biomarkers